Karl Claxton

19.9k total citations · 8 hit papers
154 papers, 13.5k citations indexed

About

Karl Claxton is a scholar working on Economics and Econometrics, General Health Professions and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Karl Claxton has authored 154 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 132 papers in Economics and Econometrics, 75 papers in General Health Professions and 16 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Karl Claxton's work include Health Systems, Economic Evaluations, Quality of Life (130 papers), Healthcare cost, quality, practices (47 papers) and Healthcare Policy and Management (38 papers). Karl Claxton is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (130 papers), Healthcare cost, quality, practices (47 papers) and Healthcare Policy and Management (38 papers). Karl Claxton collaborates with scholars based in United Kingdom, United States and Canada. Karl Claxton's co-authors include Mark Sculpher, Andrew Briggs, Elisabeth Fenwick, Anthony J. Culyer, Christopher McCabe, Laura Bojke, Stephen Palmer, Paul Revill, Su Golder and Beth Woods and has published in prestigious journals such as Nature, The Lancet and European Journal of Operational Research.

In The Last Decade

Karl Claxton

149 papers receiving 13.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Decision Modelling For Health Economic Evaluation

2006 2.3k citations Andrew Briggs, Karl Claxton et al. profile →
Representing uncertainty: the role of cost‐effectiveness acceptability curves

2001 837 citations Karl Claxton, Mark Sculpher et al. Health Economics profile →
The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies

1999 660 citations Karl Claxton profile →
The NICE Cost-Effectiveness Threshold

2008 605 citations Christopher McCabe, Karl Claxton et al. profile →
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research

2016 574 citations Beth Woods, Mark Sculpher et al. Value in Health profile →
Review of guidelines for good practice in decision-analytic modelling in health technology assessment

2004 528 citations Z Philips, Mark Sculpher et al. Health Technology Assessment profile →
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold

2015 511 citations Karl Claxton, Marta Soares et al. Health Technology Assessment profile →
Discounting in Economic Evaluations

2018 241 citations Karl Claxton et al. profile →

Peers

Countries citing papers authored by Karl Claxton

Since Specialization

Citations

This map shows the geographic impact of Karl Claxton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Claxton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Claxton more than expected).

Fields of papers citing papers by Karl Claxton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Claxton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Claxton. The network helps show where Karl Claxton may publish in the future.

Co-authorship network of co-authors of Karl Claxton

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Claxton. A scholar is included among the top collaborators of Karl Claxton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Claxton. Karl Claxton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Equitable access to costly new drugs 2025 ·BMJ ·Beth Woods, Renske M.T. ten Ham, Karl Claxton	0
2	Unpacking the care‐related quality of life effect of England's publicly funded adult social care. A panel data analysis 2024 ·Health Economics ·(unknown), (unknown), Karl Claxton, James Lomas	1
3	General-Purpose Methods for Simulating Survival Data for Expected Value of Sample Information Calculations 2023 ·Medical Decision Making ·(unknown), Eline Aas, Karl Claxton, Mark Strong, Nicky J. Welton, Torbjørn Wisløff, Anna Heath	3
4	An Efficient Method for Computing Expected Value of Sample Information for Survival Data from an Ongoing Trial 2021 ·Medical Decision Making ·(unknown), Mark Strong, Karl Claxton, Nicky J. Welton, Torbjørn Wisløff, Eline Aas	4
5	Reference Case Methods for Expert Elicitation in Health Care Decision Making 2021 ·Medical Decision Making ·Laura Bojke, Marta Soares, Karl Claxton, Abigail Colson, (unknown), Christopher Jackson, Dina Janković, Alec Morton, Linda Sharples, Andrea Taylor	27
6	Developing a reference protocol for structured expert elicitation in health-care decision-making: a mixed-methods study 2021 ·Health Technology Assessment ·Laura Bojke, Marta Soares, Karl Claxton, Abigail Colson, (unknown), Christopher Jackson, Dina Janković, Alec Morton, Linda Sharples, Andrea Taylor	46
7	Causal impact of social care, public health and healthcare expenditure on mortality in England: cross-sectional evidence for 2013/2014 2021 ·BMJ Open ·Stephen Martin, (unknown), James Lomas, Karl Claxton	20
8	Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidity 2020 ·BMJ Open ·Stephen Martin, James Lomas, Karl Claxton	27
9	Developing a Value Framework: The Need to Reflect the Opportunity Costs of Funding Decisions 2017 ·Value in Health ·Mark Sculpher, Karl Claxton, Steven D. Pearson	63
10	How to estimate the health benefits of additional research and changing clinical practice 2015 ·BMJ ·Karl Claxton, Susan Griffin, Hendrik Koffijberg, Claire McKenna	21
11	Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions 2012 ·Value in Health ·Simon Walker, Mark Sculpher, Karl Claxton, Steve Palmer	105
12	CO1 Individual Decisions and Social Value: A Conceptual Framework to Explore Alternative Decision Making Approaches and the Value of Heterogeneity in the Era of Individualized Care 2012 ·Value in Health ·Manuel Espinoza, Andrea Manca, Mark Sculpher, Karl Claxton	1
13	PRM168 An Integrated Formal Framework for Reimbursement, Research and Pricing Deliberations in Health Technology Assessment 2012 ·Value in Health ·Susan Griffin, Eldon Spackman, Marta Soares, Claire McKenna, Karl Claxton	1
14	Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development 2012 ·Health Technology Assessment ·Karl Claxton, Stephen Palmer, Louise Longworth, Laura Bojke, Susan Griffin, Claire McKenna, Marta Soares, Eldon Spackman, (unknown)	78
15	The NICE Cost-Effectiveness Threshold: What it is and What that Means 2008 ·MPRA Paper ·Christopher McCabe, Karl Claxton, (unknown)	32
16	Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses 2007 ·Health Technology Assessment ·Tim Colbourn, Christian Asseburg, Laura Bojke, Z Philips, Karl Claxton, A. E. Ades, Ruth Gilbert	58
17	Dangerous Omissions: The Consequences of Ignoring Decision Uncertainty 2007 ·SSRN Electronic Journal ·Susan Griffin, Karl Claxton, Stephen Palmer, Mark Sculpher	4
18	Decision Modelling for Health Economic Evaluation 2006 ·OUP Catalogue ·Andrew Briggs, Mark Sculpher, Karl Claxton	1
19	Decision Modelling For Health Economic Evaluation breakdown → 2006 ·Andrew Briggs, Karl Claxton, Mark Sculpher	2349
20	BAYESIAN VALUE-OF-INFORMATION ANALYSIS 2001 ·International Journal of Technology Assessment in Health Care ·Karl Claxton, Peter J. Neumann, S Araki, Milton C. Weinstein	136

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact